Literature DB >> 12823153

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.

D Pantoflickova1, G Dorta, M Ravic, P Jornod, A L Blum.   

Abstract

BACKGROUND: Rapid and consistent acid suppression on the first day of dosing may be important in treating acid-related disorders. AIM: To compare the antisecretory activity and onset of action of single doses of rabeprazole, lansoprazole, pantoprazole, omeprazole capsule, omeprazole multiple unit pellet system (MUPS) tablet and placebo in healthy Helicobacter pylori-negative subjects.
METHODS: This cross-over, double-blind, randomized study was performed in 18 H. pylori-negative subjects. Twenty-four-hour intragastric pH monitoring was performed on the day of treatment (once-daily dose of rabeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, omeprazole capsule 20 mg, omeprazole MUPS tablet 20 mg or placebo).
RESULTS: The intragastric pH (3.4) and time at pH > 4 during the 24 h post-dose (8.0 h) were significantly greater with rabeprazole than with lansoprazole, pantoprazole, omeprazole capsule, omeprazole MUPS tablet or placebo (P <or= 0.04 for rabeprazole vs. the others). Daytime and night-time pH values were higher with rabeprazole and lansoprazole than with pantoprazole, omeprazole capsule and omeprazole MUPS tablet (P </= 0.04).
CONCLUSION: Rabeprazole was the most potent acid inhibitor of all the proton pump inhibitors tested during the first day of dosing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823153     DOI: 10.1046/j.1365-2036.2003.01496.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  36 in total

1.  Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.

Authors:  Hank S Wang; David S Oh; Ariana Anderson; Jose Nieto; Phuong Tien; Gordon Ohning; Joseph R Pisegna
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

2.  Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.

Authors:  Yongqing Wang; Yaozong Yuan; Ling Meng; Hongwei Fan; Jianming Xu; Hongwen Zhang; Meifeng Wang; Hongyu Yuan; Ning Ou; Haibo Zhang; Yang Chao; Ruihua Shi
Journal:  Eur J Clin Pharmacol       Date:  2010-11-26       Impact factor: 2.953

Review 3.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.

Authors:  Takashi Ando; Takeshi Ishikawa; Satoshi Kokura; Yuji Naito; Norimasa Yoshida; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 5.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

6.  Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.

Authors:  Stanislas Bruley des Varannes; Sylvie Sacher-Huvelin; Fabienne Vavasseur; Claude Masliah; Marc Le Rhun; Philippe Aygalenq; Sylvie Bonnot-Marlier; Yves Lequeux; Jean Paul Galmiche
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

7.  Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.

Authors:  Kayoko Oda; Ryuichi Iwakiri; Megumi Hara; Kazuyo Watanabe; Akiko Danjo; Ryo Shimoda; Atsushi Kikkawa; Akifumi Ootani; Hiroyuki Sakata; Seiji Tsunada; Kazuma Fujimoto
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 8.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole.

Authors:  Elizabet V Guimarães; Paula Vp Guerra; Francisco J Penna
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

Review 10.  Insights into the future of gastric acid suppression.

Authors:  Kenneth R DeVault; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.